Shanghai Bocimed

Bocimed is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing innovative biologics for the treatment of cancer and immunological diseases. The company utilizes its proprietary AccuBody platform technology to engineer "masked" cytokines and multispecific antibodies designed to activate specifically within the tumor microenvironment, thereby reducing systemic toxicity. Its lead candidate, BJ-001, is a first-in-class tumor-targeting IL-15 fusion protein currently in Phase 1/2 clinical trials for advanced solid tumors. Bocimed's pipeline also features next-generation bispecific fusion proteins and antibody-drug conjugates targeting high-value oncology markers like PD-L1 and Claudin 18.2. The company aims to provide safer and more effective immunotherapy options for patients with refractory malignancies.